Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961145 | 0.77 | PDE10A (0.36) | TXNRD1GSRERN1PDE10AGAA | |
| SCHEMBL2083596 | 0.72 | TRIM24 (0.32) | GAATDP1L3MBTL1 | |
| SCHEMBL29779695 | 0.68 | PDE10A (0.35) | TXNRD1GSRPDE10A | |
| SCHEMBL153619 | 0.68 | PDE10A (0.35) | TXNRD1GSRPDE10A | |
| SCHEMBL4980644 | 0.68 | ERN1 (0.46) | ERN1TDP1 | |
| SCHEMBL30901452 | 0.68 | CCR4 (0.32) | — | |
| SCHEMBL28153665 | 0.68 | ERN1 (0.46) | ERN1PDE10ATDP1L3MBTL1 | |
| SCHEMBL4320020 | 0.68 | ERN1 (0.41) | ERN1TDP1 | |
| SCHEMBL21274147 | 0.68 | CCR4 (0.32) | — | |
| SCHEMBL2261210 | 0.68 | CYP1A2 (0.44) | ERN1PDE10ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633716-A4 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1633716-A2 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004094372-A2 | COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| US-6642252-B2 | Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer. | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030166685-A1 | Acid derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-1332131-A2 | ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002042273-A2 | ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-30 | — | — | WO | disclosed |
| US-6358960-B1 | FOR THERAPY OF INTRAVASCULAR COAGULATION, CORONARY THROMBOSIS, CEREBRAL INFARCTION, CEREBRAL EMBOLISM, TRANSIENT ISCHEMIC ATTACK, CEREBROVASCULAR DISORDERS, PULMONARY VASCULAR DISEASES, DEEP VENOUS THROMBOSIS, ETC. | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| EP-1078917-A1 | AMIDINO DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | TFPI, TFPI2, F2 | TXNRD1 4467/4885GSR 4798/4885ERN1 2733/4885 |
| US-20030166685-A1 | Acid derivatives useful as serine protease inhibitors | F9, F11, F12 | TXNRD1 3967/4885GSR 4383/4885ERN1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.